OPEN END TURBO LONG - ASTRAZENECA | Real-time Bid/Ask 09:39:30 12/06/2024 BST | ||
| 5.95 EUR / 5.96 EUR | +0.25% |
|
| Current month | +7.61% | ||
| 1 month | +2.59% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 11/06/24 | 5.94 | -2.62% |
| 10/06/24 | 6.1 | +2.18% |
| 07/06/24 | 5.97 | -1.65% |
| 06/06/24 | 6.07 | +2.02% |
| 05/06/24 | 5.95 | +2.06% |
Delayed Quote Börse Stuttgart
Last update June 11, 2024 at 12:04 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MC8CP6 |
| ISIN | DE000MC8CP64 |
| Date issued | 07/04/2020 |
| Strike | 7,452 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.1 € |
|---|---|
| Lowest since issue | 0.064 € |
| Spread | 0.01 € |
| Spread % | 0.17% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.4
USD
Average target price
174.4
USD
Spread / Average Target
+10.77%
- Stock Market
- Certificates
- Certificat